News Muncher - searching for bharat

2 years, 3 months ago

Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval

The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India for the Intranasal Covid-19 vaccine. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19. Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine approved by CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for …

India Bharat Biotech

2 years, 7 months ago

Covaxin Gets DCGI Nod for Kids Aged 6-12 Yrs; Corbevax Cleared for 5-12 Yr Olds; 12+ to Get Zydus Jab

News 18

In a move that could mitigate the vulnerability of children to the SAR-COV-2 virus, the Drug Controller General of India gave a restricted emergency use authorisation to three vaccines — Bharat Biotech’s Covaxin, Biological E’s Corbevax and Zydus Cadila’s ZyCov-D — for various age groups of children. Last week, the expert panel of India’s apex drug regulator recommended grant of …

India Children Age Vaccine Dcgi Bharat Biotech Covaxin

2 years, 7 months ago

Vaccine for kids: DCGI grants emergency use nod to 3 Covid vaccines for different age group of children

India TV News

Highlights India began inoculating children aged 12-14 on March 16 Countrywide vaccination drive was rolled out on January 16 last year Precaution doses to all aged above 18 yrs were allowed at private vaccination centres from April 10 Vaccine for Kids: The Drugs Controller General of India on Tuesday approved three Covid vaccines for the restricted emergency use authorisation for …

India Children Emergency Age Group Aged Dcgi

2 years, 8 months ago

India Could Start Vaccinating Younger Kids Soon as Govt Panel Suggests Covaxin for 6-12 Age Group - News18

News 18

Amid a resurgence of Covid-19 cases, especially among children, the focus is back on vaccinating kids and now, there are indications from the government that India could soon start coronavirus jabs for younger children. Covaxin in the 6-12 age group The Subject Expert Committee has recommended Bharat Biotech’s Covaxin to the Drug Controller General of India for children aged between …

India Children Sec Vaccine Aged 12 Years Dcgi

2 years, 9 months ago

DCGI Grants Emergency Use Authorisation to SII's Covid Vaccine Covovax for 12-17 Age Group

News 18

India’s central drug regulator on Wednesday granted emergency use authorisation to Serum Institute of India’s Covid-19 vaccine Covovax for the 12-17 age group subject to certain conditions. Confirming the DCGI approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted:"@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults …

India Emergency Age Group Vaccine Dcgi Emergency Use

2 years, 10 months ago

DCGI grants restricted EUA to COVID jab Corbevax for 12-18 age group

Deccan Chronicle

New Delhi/Hyderabad: The Drugs Controller General of India has granted restricted emergency use authorisation to Biological E's COVID-19 vaccine Corbevax for the 12 to 18 years age group, subject to certain conditions, official sources said on Monday. The DCGI's approval comes after the Subject Expert Committee on COVID-19 of the CDSCO on February 14 recommended granting restricted EUA to Corbevax …

India Age Covid Group Dcgi Clinical Restricted

2 years, 10 months ago

Bharat Biotech's intranasal COVID booster dose gets DGCI nod for phase 3 trials

Firstpost

An intranasal vaccine would not only be simple to administer but also reduce the use of needles, the Covaxin-maker said. ‘BBV154’ is a replication-deficient adenovirus SARS-CoV-2 vectored vaccine New Delhi/Hyderabad: India’s drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with …

India Phase Bharat Vaccine Dcgi Bharat Biotech Clinical Trial

2 years, 10 months ago

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials

India TV News

Highlights Intranasal vaccine will be administered to those who have already taken their two-dose vaccine The interval between the second dose of Covid vaccine and booster dose will be six months According to Bharat Biotech, its nasal vaccine stimulates immune responses at the site of infection The Drugs Controller General of India has granted permission to Hyderabad-based biotechnology firm Bharat …

Covid Sec Bharat Dcgi Bharat Biotech Nasal Biotech

2 years, 11 months ago

Covishield, Covaxin get govt expert panel's recommendation for regular market approval

India TV News

Highlights A DCGI Committee recommended regular market approval to Covishield and Covaxin Covishield and Covaxin are currently only authorised for emergency use in the country SII and Bharat Biotech submitted applications to DCGI seeking regular market approval An expert panel of India's central drug authority on Wednesday recommended granting regular market approval to Covid vaccines Covishield and Covaxin, which are …

Singh Expert Sec Approval Bharat Biotech Covaxin Covishield

2 years, 11 months ago

Bharat Biotech again urges health workers to be ‘highly vigilant’ while jabbing teenagers

Hindustan Times

Hyderabad-based Bharat Biotech International Limited on Tuesday urged healthcare workers to be ‘highly vigilant’ while administering jabs to teenagers aged 15 to 18, citing what it said were ‘additional reports’ stating that beneficiaries in the said age group were being jabbed with ‘unapproved Covid-19 vaccines.’ A medic administers Covid vaccine to a teen in Ludhiana at the civil surgeon’s office. …

Age Group Bharat Dcgi Bharat Biotech Covaxin Only Covaxin

2 years, 11 months ago

Bharat Biotech's nasal Covid booster dose gets DCGI approval for Phase III trial

India TV News

DCGI's Subject Expert Committee has granted 'in principle' approval to Bharat Biotech for the conduct of 'Phase III superiority study and Phase III booster dose study' for its intranasal COVID vaccine and has asked it to submit protocols for approval, according to news agency ANI. According to reports, the Hyderabad-based biotechnology company had earlier proposed that its nasal vaccine can …

India Covid Booster Bharat Biotech Dose Nasal Vaccine

2 years, 11 months ago

Bharat Biotech Seeks DCGI Nod for Trials to Evaluate Efficacy of Covaxin Booster Shot - News18

News 18

Bharat Biotech has sought permission from India’s drug regulator to conduct clinical trials for evaluating the efficacy of a third dose of its Covid-19 vaccine, Covaxin. According to a top government official, the indigenous vaccine maker has proposed to conduct clinical trials for Covaxin’s booster shot on 5,000 healthy volunteers, keeping a gap of six months between the second and …

India Booster Dcgi Dose Booster Shot Shot News18

2 years, 11 months ago

Coxavin gets DCGI nod for use among 12-18 age group

Hindustan Times

New Delhi The Drugs Controller General of India on Saturday approved Covaxin for use in children between the ages of 12 and 18, a significant step towards opening vaccinations to the age group that has so far remained ineligible in India’s immunisation programme against Covid-19. The approval from DCGI came nearly 10 weeks after the subject expert committee of the …

India Children Age Vaccine Dcgi

2 years, 11 months ago

Covaxin cleared for those above 12

The Hindu

Covaxin has been approved for use in those aged 12 and above by the Drugs Controller General of India. The DCGI in August granted emergency approval to Zycov-D, a three-dose, DNA COVID-19 vaccine developed by the Ahmedabad-based Zydus Cadilla Group, making it the first vaccine in India that could be administered to adults and those 12 and above. Welcoming the …

India Adults Vaccine Doses Dcgi 18 Years Covaxin

2 years, 11 months ago

Bharat Biotech's Covaxin gets DCGI nod for emergency use for children aged 12-18

Firstpost

With this, Covaxin becomes the second COVID-19 vaccine cleared for use for children in India. In August, Zydus Cadila’s three-dose DNA jab was allowed to be used on all over the age of 12 Bharat Biotech’s Covaxin, India’s indigenous COVID-19 vaccine, received approval from drug regulator DCGI for emergency use for children aged between 12-18 years on Saturday. Bharat Biotech …

India Children Sec Bharat Vaccine Dcgi Certain Conditions

3 years, 1 month ago

DCGI extends shelf life of Covaxin by 12 months

India Today

Covaxin-maker Bharat Biotech on Wednesday, November 3, received an extension of 12 months on the shelf life of the Covid vaccine. After a thorough review of sterility and stability studies, DCGI recommended approval for the extension of the shelf life of the vaccines. WATCH | Bharat Biotech's Covaxin on the brink of WHO approval "The CDSCO has approved the extension …

Life Vaccine Shelf Extension 12 Months Bharat Biotech Shelf Life

3 years, 1 month ago

Serum Institute seeks DCGI nod for Covid vaccine Covovax

India Today

The Serum Institute of India on Friday sought permission from the Drugs Controller General of India to manufacture Covid-19 vaccine Covovax for restricted use in emergency situations at its Manjari manufacturing site, official sources said. There were no safety concerns arising from the study data and Covovax is safe and immunogenic in the adult population, Prakash Kumar Singh, Director, Government …

Covid Vaccine Serum Institute Covovax India Sii Dcgi Nod

3 years, 2 months ago

Bharat Biotech submits data to DCGI for Covaxin for children in 2-18 age group | Exclusive

India Today

Bharat Biotech, the manufacturer of indigenously developed Covid-19 vaccine Covaxin, has submitted the trial data for children in the 2-18 years age group to the Drugs and Comptroller General of India, the company’s chairman and managing director Dr Krishna Ella told India Today on Saturday. Bharat Biotech completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of …

India Bharat Dcgi Bharat Biotech Biotech Covaxin Krishna Ella

3 years, 3 months ago

DCGI nod to phase-I clinical trial of COVID-19 vaccine of Reliance Life Sciences

The Hindu

The Drugs Controller General of India on September 3 granted permission to the Mukesh Ambani-owned Reliance Life Sciences to conduct phase-I clinical trial of its indigenous COVID-19 vaccine with certain conditions, sources said. The phase-I clinical trial will be conducted to evaluate safety, tolerability and immunogenicity of the SARS-CoV-2 recombinant protein subunit vaccine in healthy volunteers according to protocol, they …

Trial Dcgi

3 years, 4 months ago

Proposal to study mixing of Covaxin, Covishield approved by DCGI

India TV News

The Drugs Controller General Of India, India's drug regulator, has approved a proposal for a study to be conducted on the mixing of two COVID-19 vaccines -- Covishield and Covaxin. The aim of the study will be to assess the feasibility on whether a person can be given two different vaccine shots -- one each of Covishield and Covaxin -- …

India Medical Research Study Vaccine Dcgi Research Icmr Covaxin

3 years, 6 months ago

Why WHO assessment of safety and efficacy is essential for Covaxin to get nod for global emergency use

Firstpost

WHO has said that a COVID-19 vaccine should at least show the efficacy of 50 percent in mandated trials and Covaxin clears this requirement with its latest Phase-3 results With 77.8 percent efficacy rate and at least over 2.5 crore doses administered so far, Covaxin is up for evaluation by WHO as India’s only indigenously created COVID-19 vaccine eyes an …

Health India Emergency Trials Vaccines Clinical Trials Covid

3 years, 6 months ago

Bharat Biotech submits Covaxin's Phase III trial data to DCGI: Govt sources

India TV News

The Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to Drugs Controller General of India over the weekend, according to government sources. "We have received the data from the phase III trials," a senior government official confirmed. The phase III data of its vaccine have been questioned various times and that …

India Dcgi Covid Vaccine Bharat Biotech Iii Data

3 years, 6 months ago

Covaxin trial on children begins at AIIMS Patna

Live Mint

Patna's All India Institute of Medical Sciences has started the paediatric trials for the COVID-19 vaccine manufactured by the Bharat Biotech, Covaxin, reported news agency ANI. Covaxin received the Drugs Controller General of India nod to conduct clinical trials in children on May 11. VK Paul, Member, Niti Aayog had earlier said, "Covaxin has been approved by the Drugs Controller …

India Covaxin Trial

3 years, 7 months ago

Bharat Biotech to conduct Covaxin trial on age group between 2 and 18, DCGI gives nod

Hindustan Times

The Drug Controller General of India on Thursday gave permission to Bharat Biotech to conduct clinical trials of its Covid-19 vaccines Covaxin on children belonging to the age group of 2 to 18 years. Covaxin trial on children below 18 years will take place at AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur. The proposal was deliberated …

India Trial Bharat Children Age Bharat Biotech 18 Years Biotech

Filters

Articles for Dcgi, search results for bharat

Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval

Covaxin Gets DCGI Nod for Kids Aged 6-12 Yrs; Corbevax Cleared for 5-12 Yr Olds; 12+ to Get Zydus Jab

Vaccine for kids: DCGI grants emergency use nod to 3 Covid vaccines for different age group of children

India Could Start Vaccinating Younger Kids Soon as Govt Panel Suggests Covaxin for 6-12 Age Group - News18

DCGI Grants Emergency Use Authorisation to SII's Covid Vaccine Covovax for 12-17 Age Group

DCGI grants restricted EUA to COVID jab Corbevax for 12-18 age group

Bharat Biotech's intranasal COVID booster dose gets DGCI nod for phase 3 trials

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials

Covishield, Covaxin get govt expert panel's recommendation for regular market approval

Bharat Biotech again urges health workers to be ‘highly vigilant’ while jabbing teenagers

Bharat Biotech's nasal Covid booster dose gets DCGI approval for Phase III trial

Bharat Biotech Seeks DCGI Nod for Trials to Evaluate Efficacy of Covaxin Booster Shot - News18

Coxavin gets DCGI nod for use among 12-18 age group

Covaxin cleared for those above 12

Bharat Biotech's Covaxin gets DCGI nod for emergency use for children aged 12-18

DCGI extends shelf life of Covaxin by 12 months

Serum Institute seeks DCGI nod for Covid vaccine Covovax

Bharat Biotech submits data to DCGI for Covaxin for children in 2-18 age group | Exclusive

DCGI nod to phase-I clinical trial of COVID-19 vaccine of Reliance Life Sciences

Proposal to study mixing of Covaxin, Covishield approved by DCGI

Why WHO assessment of safety and efficacy is essential for Covaxin to get nod for global emergency use

Bharat Biotech submits Covaxin's Phase III trial data to DCGI: Govt sources

Covaxin trial on children begins at AIIMS Patna

Bharat Biotech to conduct Covaxin trial on age group between 2 and 18, DCGI gives nod